Literature DB >> 18205180

Cdk9/Cyclin T1 complex: a key player during the activation/differentiation process of normal lymphoid B cells.

Giulia De Falco1, Eleonora Leucci, Anna Onnis, Cristiana Bellan, Chiara Tigli, Stefan Wirths, Giovanna Cerino, Mario Cocco, Domenica Crupi, Antonio De Luca, Antonio Lanzavecchia, Piero Tosi, Lorenzo Leoncini, Antonio Giordano.   

Abstract

Cdk9/Cyclin T1 complex is very important in controlling specific differentiative pathways of several cell types. Limited data are available regarding the expression of Cdk9/Cyclin T1 in hematopoietic and lymphoid tissues. Cdk9/Cyclin T1 expression seems to be related to particular stages of lymphoid differentiation/activation. In this study, we observed that the expression level of Cdk9/Cyclin T1 in vivo increases in memory B cells compared to naïve B cells, and in activated B cells, compared to non-activated ones. The expression level of the Cdk9/Cyclin T1 complex does not increase in cells induced to differentiate in vitro. In addition, we showed that Cdk9 interacts with E12 and E47, specifically activated during Germinal Center (GC) reaction. Taken together this data suggests an active role for the Cdk9/Cyclin T1 complex during lymphoid differentiation through germinal center reaction. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18205180     DOI: 10.1002/jcp.21311

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  A Network of Regulations by Small Non-Coding RNAs: The P-TEFb Kinase in Development and Pathology.

Authors:  Hossein Ghanbarian; Valérie Grandjean; François Cuzin; Minoo Rassoulzadegan
Journal:  Front Genet       Date:  2011-12-28       Impact factor: 4.599

Review 2.  Cellular and Molecular Mechanisms of R/S-Roscovitine and CDKs Related Inhibition under Both Focal and Global Cerebral Ischemia: A Focus on Neurovascular Unit and Immune Cells.

Authors:  Lucas Le Roy; Anne Letondor; Cloé Le Roux; Ahmed Amara; Serge Timsit
Journal:  Cells       Date:  2021-01-08       Impact factor: 6.600

3.  Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development.

Authors:  Gaetano Romano
Journal:  ISRN Oncol       Date:  2013-06-06

Review 4.  Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.

Authors:  Vladimír Krystof; Sonja Baumli; Robert Fürst
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation.

Authors:  Yeming Han; Shanshan Zhao; Yaoqin Gong; Guihua Hou; Xi Li; Li Li
Journal:  Oncotarget       Date:  2016-01-12

6.  Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis.

Authors:  Annelie Hellvard; Lutz Zeitlmann; Ulrich Heiser; Astrid Kehlen; André Niestroj; Hans-Ulrich Demuth; Joanna Koziel; Nicolas Delaleu; Piotr Mydel
Journal:  Sci Rep       Date:  2016-08-11       Impact factor: 4.379

7.  The CDK9-cyclin T1 complex mediates saturated fatty acid-induced vascular calcification by inducing expression of the transcription factor CHOP.

Authors:  Yuji Shiozaki; Kayo Okamura; Shohei Kohno; Audrey L Keenan; Kristina Williams; Xiaoyun Zhao; Wallace S Chick; Shinobu Miyazaki-Anzai; Makoto Miyazaki
Journal:  J Biol Chem       Date:  2018-09-12       Impact factor: 5.157

8.  Cyclin-dependent kinase 9 expression and its association with CD8+ T cell infiltration in microsatellite-stable colorectal cancer.

Authors:  Jiefu Wang; Jia Liu; Fei Tian; Yang Zhan; Dalu Kong
Journal:  Oncol Lett       Date:  2019-10-08       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.